Document is current
Any future updates will be listed below
-
Authors
Sperk, Elena
Lemanski, Claire
Neumaier, Christian
Lauer, Juliane
Siefert, Victor
Völker, Ragna
Lindner, Christoph
Niehoff, Peter
Tallet, Agnes Richard
Racadot, Séverine
Petit, Adeline
Pazos, Montserrat
Le-Blanc Onfroy, Magali
Martin, Etienne
Reuter, Christiane
Hermann, Robert Michael
Pohl, Fabian
Friedrichs, Kay
Würschmidt, Florian
Pigorsch, Steffi
Kolberg, Hans-Christian
Graf, Heiko
Brunner, Thomas B.
Malter, Wolfram
Park-Simon, Tjoung-Wong
Brucker, Cosima
Fleckenstein, Jochen
Petersen, Cordula
Tuschy, Benjamin
Wilken, Eva Ekas
Büttner, Sylvia
Sütterlin, Marc
Flyger, Henrik
Wenz, Frederik
-
Funding
Funding for this research was provided by:
Ruprecht-Karls-Universität Heidelberg
- License Information
-
More Information
Article History
Received: 18 June 2025
Accepted: 3 November 2025
First Online: 4 December 2025
Declarations
:
: All patients signed informed consent to participate in the study. The protocol and all amendments were approved by the Ethics Committee II at Heidelberg University, Medical Faculty Mannheim with the number 2009-303Strahl.-MA. The study is also under supervision of the Bundesamt für Strahlenschutz (national authority for radiation protection). We confirm that all experiments were performed in accordance with relevant guidelines and regulations.
: Not applicable.
: E. Sperk, M. Sütterlin and R. M. Hermann received honoraria and travel expenses from Carl Zeiss Meditec. H.-C.Kolberg has received honoraria from Pfizer, Seagen, Novartis, Roche, Genomic Health/Exact Sciences, Amgen, AstraZeneca, Riemser, Carl Zeiss Meditec, TEVA, Theraclion, Janssen-Cilag, GSK, LIV Pharma, Lilly, SurgVision, Onkowissen, Gilead, Daiichi Sankyo, Stemline and MSD, travel support from Carl Zeiss Meditec, LIV Pharma, Novartis, Amgen, Pfizer, Daiichi Sankyo, Gilead, Stemline, Tesaro and owns stock of Theraclion SA.
